Physician profile
Kelsey Pan
NPI 1891290748
$3,955.42
in general payments reported to CMS, 2019-2025
14 companies · $2,005 in 2025
The $2,005 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.05 · 2022: $307 · 2023: $1,132 · 2024: $419 · 2025: $2,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,345 · Consulting Fee: $1,000 · Education: $754 · Travel and Lodging: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,344.70 |
| Consulting Fee | $1,000.00 |
| Education | $753.81 |
| Travel and Lodging | $458.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,589.46 | 2024-2025 | Rybrevant, Talvey, Tecvayli |
| Lilly USA, LLC | $847.59 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $257.41 | 2019-2024 | Keytruda |
| Rigel Pharmaceuticals, INC. | $241.56 | 2022-2023 | Rezlidhia, Tavalisse |
| Astrazeneca Pharmaceuticals LP | $230.62 | 2023 | Enhertu |
| Janssen Pharmaceuticals, INC | $146.32 | 2022-2023 | Xarelto |
| Pfizer INC. | $136.37 | 2023-2024 | |
| Gilead Sciences, INC. | $121.82 | 2023 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $99.60 | 2024 | Libtayo |
| Amgen INC. | $87.20 | 2024-2025 | Vectibix, Imdelltra (Amg 757), Lumakras |
| Abbvie INC. | $66.23 | 2023 | |
| Janssen Scientific Affairs, LLC | $61.82 | 2022 | |
| Pharmacosmos Therapeutics INC. | $36.46 | 2023 | Monoferric |
| Jazz Pharmaceuticals INC. | $32.96 | 2023 | Zepzelca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Pan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.